Zika virus

IRIS guide for applicants - How to create and submit scientific applications, for industry and individual applicants

Retrieved on: 
Dienstag, Mai 28, 2024
Transfer, Steps, Scroll, SPC, Q&A, Google Chrome, European Medicines Agency, VET, Lead, Product lifecycle, Medical device, EMA, GVP, Canonical form, Common, NOT, Companion, PO, Chikungunya, Nature, Location, Button, Sponsor, Task force, PV, Web browser, Public, Workflow, Iris, Outcome, Purchase order, Partex Group, Prevalence, Update, Person, Medicine, Committee, Record, Approximation error, Protocol, Risk, Availability, EEA, Bulk, CVMP, Figure, Signal, PHE, Language, Zika virus, ECTD, Letter, SharePoint, Authorization, Name, Communication, Inspectorate, MIA, PRIME, MAA, Reproduction, European, Glass, Chromium, Section, Marketing, PIP, EAF, Organization, Safety, PLM, Mode, SAS, Treatment, ETF, Sunset, MAH, Standard, MSD, Directive 2001/83/EC, GMP, Public health, Self-management, Union, MSO, Report, Microsoft Excel, Browser, GCP, Civil service commission, N.B, Common Technical Document, VSI, Section 8, Qualification, Withdrawal, Date, Draft, SME, Abbreviation, Access management, Headquarters, PDF, Diagnosis, Section 4, HR, State, History, NEXT, PASS, PSMF, RPI, Save, MB, Inspection, SAP, COVID, Process, Research, Validation, VS, SAWP, Art, European Commission, Translation, Literature, PD, Public Security Section 9, Clinical trial, PRI, Brief, Submission, Annual report, ITF, KOM, Substance, Marketing authorisation, Parallel, Documentation, Contact lens, Human, CHMP, Risk management

IRIS guide for applicants - How to create and submit scientific applications, for industry and individual applicants

Key Points: 

    Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates

    Retrieved on: 
    Dienstag, Mai 7, 2024
    FDA, VLA, Bank statement, Fast Track, Research, CHMP, Trial of the century, Biologics license application, Coalition, Profit & Loss, OrbiMed, Lyme disease, Bavarian Nordic, CDC, Notifiable disease, Adolescence, Income tax, Chikungunya, Third party, ACIP, BLA, Licensure, CEPI, PRV, Safety, Travel, Indoor Living, EMA, Marketing, USD, Sale, Tropical disease, EDT, Depreciation, MAA, Profit, Euronext Paris, Zika virus, Epidemic, Adjustment, COGS, Saint-Herblain, COVID-19, Growth, Ageing

    Saint-Herblain (France), May 7, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported its financial results for the first quarter ending March 31, 2024, and provided corporate updates.

    Key Points: 
    • Saint-Herblain (France), May 7, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported its financial results for the first quarter ending March 31, 2024, and provided corporate updates.
    • The condensed consolidated interim financial results are available on the Company’s website ( Financial Reports – Valneva ).
    • In the first quarter of 2024, IXIARO®/JESPECT® sales were €16.6 million compared to €17.4 million in the first quarter of 2023.
    • IXIARO®/JESPECT® sales were €16.6 million in the first quarter of 2024 compared to €17.4 million in the first quarter of 2023.

    Biotech Innovations Aim to Combat Soaring Cancer Diagnoses by 2050

    Retrieved on: 
    Mittwoch, Mai 1, 2024
    FDA, Protein, APC, MRNA, Risk, Moderna, News, Death, Partnership, Skin cancer, Vaccine, ASCO, Spyglass, AACR, NK, Lung cancer, Colorectal cancer, CNBC, NMIBC, Infection, DPX, Messenger, CD8, Merck, NSCLC, RSV, Autumn, Safety, Triangle, Survival, American Cancer Society, DNA, Therapy, Medicine, Melanoma, Pembrolizumab, Biology, Peanut, Cancer, A9, Interview, Immunotherapy, DSM-IV codes, HSV, Habit, Zika virus, COVID-19, Disease, Patent, Patient, Society, Acquisition, Peptide, Antigen, Immune system

    VANCOUVER, BC, May 1, 2024 /PRNewswire/ -- USA News Group – An alarming trend is happening around the world, where tens of millions of progressively younger people are being diagnosed with of cancer. A new report from the American Cancer Society projects that by 2050, the number of people diagnosed with cancer could rise by 77%. According to experts at last year's annual American Society of Clinical Oncology (ASCO) meeting, a little-known bacteria could be behind the rising rates of cancer in people under 40, along with pointing towards bad habits such as highly-processed diets and heavy alcohol use being potential catalysts. While five-year cancer survival rates are on an upward trend, the biotech sector is racing to meet these challenges head on with new treatments and safeguards against cancer, including recent developments from companies such as BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF), Moderna, Inc. (NASDAQ: MRNA), Boundless Bio, Inc. (NASDAQ: BOLD), ImmunityBio, Inc. (NASDAQ: IBRX), and MacroGenics, Inc. (NASDAQ: MGNX).

    Key Points: 
    • A new report from the American Cancer Society projects that by 2050, the number of people diagnosed with cancer could rise by 77%.
    • "We now have massive opportunities in oncology, infectious disease, allergy desensitization, and autoimmune diseases," said Kenneth Kovan, President and Chief Operating Officer of BioVaxys.
    • The joint Moderna/Merck efforts are also testing the vaccine with Keytruda against other tumor types, including non-small cell lung cancer.
    • This shot is designed to train the immune system to recognize and attack specific mutations in cancer cells.

    Biotech Innovations Aim to Combat Soaring Cancer Diagnoses by 2050

    Retrieved on: 
    Mittwoch, Mai 1, 2024
    FDA, Protein, APC, MRNA, Risk, Moderna, News, Death, Partnership, Skin cancer, Vaccine, ASCO, Spyglass, AACR, NK, Lung cancer, Colorectal cancer, CNBC, NMIBC, Infection, DPX, Messenger, CD8, Merck, NSCLC, RSV, Autumn, Safety, Triangle, Survival, American Cancer Society, DNA, Therapy, Medicine, Melanoma, Pembrolizumab, Biology, Peanut, Cancer, A9, Interview, Immunotherapy, DSM-IV codes, HSV, Habit, Zika virus, COVID-19, Disease, Patent, Patient, Society, Acquisition, Peptide, Antigen, Immune system

    VANCOUVER, BC, May 1, 2024 /PRNewswire/ -- USA News Group – An alarming trend is happening around the world, where tens of millions of progressively younger people are being diagnosed with of cancer. A new report from the American Cancer Society projects that by 2050, the number of people diagnosed with cancer could rise by 77%. According to experts at last year's annual American Society of Clinical Oncology (ASCO) meeting, a little-known bacteria could be behind the rising rates of cancer in people under 40, along with pointing towards bad habits such as highly-processed diets and heavy alcohol use being potential catalysts. While five-year cancer survival rates are on an upward trend, the biotech sector is racing to meet these challenges head on with new treatments and safeguards against cancer, including recent developments from companies such as BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF), Moderna, Inc. (NASDAQ: MRNA), Boundless Bio, Inc. (NASDAQ: BOLD), ImmunityBio, Inc. (NASDAQ: IBRX), and MacroGenics, Inc. (NASDAQ: MGNX).

    Key Points: 
    • A new report from the American Cancer Society projects that by 2050, the number of people diagnosed with cancer could rise by 77%.
    • "We now have massive opportunities in oncology, infectious disease, allergy desensitization, and autoimmune diseases," said Kenneth Kovan, President and Chief Operating Officer of BioVaxys.
    • The joint Moderna/Merck efforts are also testing the vaccine with Keytruda against other tumor types, including non-small cell lung cancer.
    • This shot is designed to train the immune system to recognize and attack specific mutations in cancer cells.

    Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate

    Retrieved on: 
    Dienstag, März 26, 2024
    Notifiable disease, Saint-Herblain, Zika virus, JE, COVID-19, VLA2001, Ageing, Public, Chikungunya, Woman, Mosquito-borne disease, VLA, Safety, Euronext Paris, Access, CpG, Food, Vaccine

    Saint-Herblain (France), March 26, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the initiation of a Phase 1 clinical trial to investigate the

    Key Points: 
    • Saint-Herblain (France), March 26, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the initiation of a Phase 1 clinical trial to investigate the
      the safety and immunogenicity of VLA1601, its second-generation adjuvanted inactivated vaccine candidate against the Zika virus (ZIKV).
    • The randomized, placebo-controlled, Phase 1 trial, VLA1601-102, is planned to enroll approximately 150 participants aged 18 to 49 years in the United States.
    • Phase 1 results from Valneva’s first-generation Zika vaccine candidate were reported in 2018 showing a favorable safety profile and immunogenicity in all tested doses and schedules2.
    • This preference stems from the understanding that the primary recipients of a Zika vaccine are anticipated to be women of childbearing age, potentially including those who are pregnant.

    BioVaxys Announces Allowance of DPX-Related Patent for Japan and Filing of Additional International Patent Applications

    Retrieved on: 
    Dienstag, März 5, 2024
    RSV, Cancer, Messenger, Infection, FRA, Patent, APC, PCT, Patent Cooperation Treaty, HSV, Antibody, IMV, Peptide, Antigen, Protein, Intellectual property, Zika virus, Immune system, Vaccine

    This Patent was part of the extensive Intellectual Property portfolio recently acquired by BioVaxys from the former IMV, Inc.

    Key Points: 
    • This Patent was part of the extensive Intellectual Property portfolio recently acquired by BioVaxys from the former IMV, Inc.
    • This Patent has already been issued in the US, and is currently pending in the EU.
    • BioVaxys also is pleased to announce it filed an international patent application through the Patent Cooperation Treaty ("PCT") from two pending patent applications in the US related to methods of formulating DPX™ compositions that comprise both a lipid-based adjuvant (i.e.
    • The PCT is a patent treaty with more than 150 member countries, makes it possible to seek patent protection for an invention simultaneously in a large number of countries by filing a single "international" patent application instead of filing several separate national or regional patent applications.

    QIAGEN announces partnership with Penn State University to advance microbiome sciences

    Retrieved on: 
    Donnerstag, Januar 25, 2024
    Senior, Student, Chitin, NGS, Research, Microbiome, Arthropod, Animal, Health, RNA, Partnership, Joint, Spider, Faculty, Genetics, Pennsylvania State University, Skeleton, Real-time, Environment, Bacteria, Arbovirus, Human, Reproduction, Entomology, Dengue fever, State College, Pennsylvania, Laboratory, Zika virus, QIAGEN, MITES, Virus, Organization, Wolbachia, Plant, PCR, Automation, Ecology, Education, QGEN, Nested polymerase chain reaction, Fungus, Antibiotics

    Germantown, Maryland, and State College, Pennsylvania, Jan. 25, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a first-in-kind collaboration with Penn State University in the United States to create a shared research and education facility for the fast-developing microbiome sciences.

    Key Points: 
    • Germantown, Maryland, and State College, Pennsylvania, Jan. 25, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a first-in-kind collaboration with Penn State University in the United States to create a shared research and education facility for the fast-developing microbiome sciences.
    • In doing so, this new partnership will provide QIAGEN with a site to support the development of new products as a testing center.
    • This includes an internship program for graduate students from Penn State at QIAGEN laboratories at the European operational headquarters in Hilden, Germany, and helps them prepare for careers in the biotechnology industry.
    • “Additionally, it will foster relationships with the microbiome research community and enable us to better develop new products for microbiome research based on direct customer feedback.”
      Seth Bordenstein, Director of the One Health Microbiome Center, Professor of Biology and Entomology, and Huck Endowed Chair in the Microbiome Sciences, at Penn State said: “The ‘One Health’ vision shared by QIAGEN and Penn State University is critical for microbiome research.

    Moleculin Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B/3

    Retrieved on: 
    Mittwoch, Januar 24, 2024
    Northwestern University, Neutrophil, Patient, Research, OS, Acute myeloid leukemia, Anthracycline, Culture, Survival, Mouse, CRS, Thrombocytopenia, Safety, Allergy, STS, GBM, PFS, Febrile neutropenia, Bone marrow, Cardiotoxicity, NIH, Glioblastoma, Brain, Zika virus, FDA, Virus, HIV, Aplastic anemia, National Institutes of Health, AML, Clinical trial, Bangladesh Technical Education Board, SARS-CoV-2, Pharmacokinetics, ITT, Pharmaceutical industry

    "Over the course of 2023, we delivered on our promise for a year of important data from our Annamycin clinical development programs.

    Key Points: 
    • "Over the course of 2023, we delivered on our promise for a year of important data from our Annamycin clinical development programs.
    • We are well-positioned to continue building upon our encouraging growing body of preliminary clinical data and transition to pivotal Phase 2B/3 clinical trials by year-end 2024.
    • With our recent financing in December 2023, we have extended our runway into the fourth quarter of 2024, as well.
    • WP1122 successfully completed a Phase 1 clinical trial, which established a recommended safe dose for future potential Phase 1B or Phase 2 clinical trials.

    Global mRNA Platform Market Research Report 2023-2028: Post COVID-19 Vaccines, mRNA's Promise in Cancer Immunotherapy and Personalized Medicine

    Retrieved on: 
    Freitag, Dezember 1, 2023
    Pandemic, Medicine, Attention, Regenerative medicine, Massive parallel sequencing, Pfizer, Immune system, Organization, Haemophilia, Vaccine, RSV, Respiratory syncytial virus, Allergy, Disease, Cancer, Biotechnology, Protein, Patient, DSM-IV codes, Zika virus, Cas9, D-bifunctional protein deficiency, Autoimmune disease, Infection, Messenger, COVID-19, LNP, HIV, BioNTech, CRISPR, Growth, NGS, SARS-CoV-2, Cell, Temperature, Health, RNA

    In cancer immunotherapy, for example, mRNA is designed to instruct immune cells to target and attack cancer cells, harnessing the body's immune system to fight the disease.

    Key Points: 
    • In cancer immunotherapy, for example, mRNA is designed to instruct immune cells to target and attack cancer cells, harnessing the body's immune system to fight the disease.
    • The Global mRNA Platform Market is poised for remarkable growth, driven by significant advancements, emerging applications, and robust growth drivers.
    • The Global mRNA Platform Market is on an upward trajectory, driven by advancements, emerging applications, and a global response to pandemics.
    • Company Profiles: Detailed analysis of the major companies present in the Global mRNA Platform Market.

    Global mRNA Vaccine Market Research Report 2023: On-going Clinical Trials, Drug Pipeline, Mergers & Acquisitions, & Product Launches - ResearchAndMarkets.com

    Retrieved on: 
    Freitag, November 3, 2023
    Health, Pharmaceutical, Perelman School of Medicine at the University of Pennsylvania, Pharmacology, Infection, ClinicalTrials.gov, Vaccine, SARS-CoV-2, RNA, Antigen, Biotechnology, Mortality, Penn, Mutation, Safety, HIV, Cytokine, University, TSA, Research, Cell, Protein, Arcturus Therapeutics, Application, Death, COVID-19 vaccine, Pfizer, Growth, Genome, Vaccination, Lipid, COVID-19, Risk, Viral, Immunity, TAA, Competition, Messenger, DSM-IV codes, MRNA vaccine, Cancer, Investment, Therapy, Patient, Toxicity, Zika virus, Rabies virus, DNA

    Global mRNA vaccine market is poised to grow at an impressive rate to 2028 on account of the various benefits of mRNA vaccine over DNA vaccine in terms of production, safety, efficacy, and distribution, among others.

    Key Points: 
    • Global mRNA vaccine market is poised to grow at an impressive rate to 2028 on account of the various benefits of mRNA vaccine over DNA vaccine in terms of production, safety, efficacy, and distribution, among others.
    • The global mRNA vaccine market experiences growth driven by the increasing occurrence of cancer, genetic anomalies, and viral infections.
    • This has prompted numerous biotechnology and pharmaceutical companies, along with academic and research institutions, to engage in research, development, and clinical trials for various mRNA vaccines.
    • This, in turn, creates promising prospects for the global mRNA vaccine market during the forecast period.